Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Household transmission of Neisseria meningitidis in the African meningitis belt: a longitudinal cohort study.

MenAfriCar Consortium.

Lancet Glob Health. 2016 Dec;4(12):e989-e995. doi: 10.1016/S2214-109X(16)30244-3.

2.

Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.

Souza AR, Maruyama CM, Sáfadi MA, Lopes MH, Azevedo RS, Findlow H, Bai X, Borrow R, Weckx LY.

Vaccine. 2016 Aug 5;34(36):4327-34. doi: 10.1016/j.vaccine.2016.06.072. Epub 2016 Jul 6.

PMID:
27395566
3.

Correction: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

Manigart O, Trotter C, Findlow H, Aseffa A, Mihret W, Moti Demisse T, Yeshitela B, Osei I, Hodgson A, Quaye SL, Sow S, Coulibaly M, Diallo K, Traore A, Collard JM, Moustapha Boukary R, Djermakoye O, Mahamane AE, Jusot JF, Sokhna C, Alavo S, Doucoure S, Ba EH, Dieng M, Diallo A, Daugla DM, Omotara B, Chandramohan D, Hassan-King M, Nascimento M, Woukeu A, Borrow R, Stuart JM, Greenwood B.

PLoS One. 2016 Jul 5;11(7):e0158938. doi: 10.1371/journal.pone.0158938. eCollection 2016.

4.

Children with Haemophilus influenzae type b (Hib) vaccine failure have long-term bactericidal antibodies against virulent Hib strains with multiple capsular loci.

Townsend-Payne K, Ladhani SN, Findlow H, Slack M, Borrow R.

Vaccine. 2016 Jul 25;34(34):3931-4. doi: 10.1016/j.vaccine.2016.06.033. Epub 2016 Jun 20.

PMID:
27317452
5.

What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience.

Findlow H, Borrow R.

Paediatr Drugs. 2016 Apr;18(2):83-7. doi: 10.1007/s40272-016-0169-1.

PMID:
26913860
6.

A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

Manigart O, Trotter C, Findlow H, Assefa A, Mihret W, Moti Demisse T, Yeshitela B, Osei I, Hodgson A, Quaye SL, Sow S, Coulibaly M, Diallo K, Traore A, Collard JM, Moustapha Boukary R, Djermakoye O, Mahamane AE, Jusot JF, Sokhna C, Alavo S, Doucoure S, Ba el H, Dieng M, Diallo A, Daugla DM, Omotara B, Chandramohan D, Hassan-King M, Nascimento M, Woukeu A, Borrow R, Stuart JM, Greenwood B.

PLoS One. 2016 Feb 12;11(2):e0147928. doi: 10.1371/journal.pone.0147928. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0158938.

7.

Interactions of conjugate vaccines and co-administered vaccines.

Findlow H, Borrow R.

Hum Vaccin Immunother. 2016;12(1):226-30. doi: 10.1080/21645515.2015.1091908. Review.

8.

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Holme D, Findlow H, Sow SO, Idoko OT, Preziosi MP, Carlone G, Plikaytis BD, Borrow R.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S563-9. doi: 10.1093/cid/civ505.

9.

Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.

Price GA, Hollander AM, Plikaytis BD, Mocca BT, Carlone G, Findlow H, Borrow R, Sow SO, Diallo A, Idoko OT, Enwere GC, Elie C, Preziosi MP, Kulkarni PS, Bash MC.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S554-62. doi: 10.1093/cid/civ504.

PMID:
26553688
10.

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

Basta NE, Borrow R, Berthe A, Dembélé AT, Onwuchekwa U, Townsend K, Boukary RM, Mabey L, Findlow H, Bai X, Sow SO.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S547-53. doi: 10.1093/cid/civ602.

11.

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.

Tall H, Yaro S, Kpoda HB, Ouangraoua S, Trotter CL, Njanpop Lafourcade BM, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo JB, Gessner BD, Borrow R, Mueller JE.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S540-6. doi: 10.1093/cid/civ519.

12.

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S521-30. doi: 10.1093/cid/civ518.

13.

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S514-20. doi: 10.1093/cid/civ672.

14.

Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.

Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, England A, Matheson M, Bai X, Findlow H, Burbidge P, Thalasselis V, Hallis B, Goldblatt D, Borrow R, Heath PT, Miller E.

Clin Infect Dis. 2015 Dec 1;61(11):1637-44. doi: 10.1093/cid/civ695. Epub 2015 Sep 15.

PMID:
26374816
15.

Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.

Ishola DA, Andrews N, Waight P, Yung CF, Southern J, Bai X, Findlow H, Matheson M, England A, Hallis B, Findlow J, Borrow R, Miller E.

Pediatr Infect Dis J. 2015 Aug;34(8):865-74. doi: 10.1097/INF.0000000000000750.

PMID:
26075813
16.

Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.

Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R.

Vaccine. 2015 Jun 26;33(29):3322-30. doi: 10.1016/j.vaccine.2015.05.027. Epub 2015 May 27.

PMID:
26025807
17.

Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

Findlow H, Borrow R.

Hum Vaccin Immunother. 2015;11(6):1501-6. doi: 10.1080/21645515.2015.1019189. Review.

18.

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.

MenAfriCar consortium.

J Infect Dis. 2015 Oct 15;212(8):1298-307. doi: 10.1093/infdis/jiv211. Epub 2015 Apr 9.

19.

Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.

Brodszki N, Skattum L, Bai X, Findlow H, Borrow R, Jönsson G.

Vaccine. 2015 Apr 8;33(15):1839-45. doi: 10.1016/j.vaccine.2015.02.025. Epub 2015 Feb 21.

PMID:
25707694
20.

Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.

Iro MA, Khatami A, Marshall AS, Pace D, Voysey M, McKenna J, Campbell D, Attard-Montalto S, Finn A, White C, Faust SN, Kent A, Heath PT, MacLeod E, Stanford E, Findlow H, Almond R, Bai X, Borrow R, Snape MD, Pollard AJ.

Lancet Infect Dis. 2015 Feb;15(2):172-80. doi: 10.1016/S1473-3099(14)71057-6. Epub 2015 Jan 8.

PMID:
25577661

Supplemental Content

Loading ...
Support Center